GlassScriptPhysician profile
Mark Louis Segal
NPI 1093715385
$14,886.23
in general payments reported to CMS, 2019-2025
83 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $635 · 2021: $879 · 2022: $1,744 · 2023: $5,389 · 2024: $3,700 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,996.57 |
| Education | $131.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,812.61 | 2019-2025 | Cabometyx |
| Eisai INC. | $862.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $732.07 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Novartis Pharmaceuticals Corporation | $593.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $511.57 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $448.42 | 2020-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $445.43 | 2020-2025 | Alunbrig, Iclusig, Fruzaqla |
| Pfizer INC. | $436.92 | 2020-2025 | |
| Incyte Corporation | $367.84 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $350.10 | 2019-2024 | Padcev, Adcetris, Tukysa |
| Gilead Sciences, INC. | $294.18 | 2022-2025 | Trodelvy |
| Celgene Corporation | $286.59 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $279.81 | 2022-2025 | Padcev, Vyloy, Xtandi |
| Beigene USA, INC. | $259.16 | 2020-2025 | Brukinsa |
| Genentech USA, INC. | $257.06 | 2021-2024 | Venclexta, Tecentriq, Polivy |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $247.99 | 2020-2025 | Bavencio, Tepmetko |
| Lilly USA, LLC | $238.39 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Taiho Oncology, INC. | $226.60 | 2019-2025 | |
| Janssen Biotech, INC. | $225.17 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Glaxosmithkline, LLC. | $209.00 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Karyopharm Therapeutics INC. | $208.09 | 2020-2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $197.81 | 2020-2025 | Opdivo |
| Amgen INC. | $197.05 | 2019-2023 | Lumakras |
| Array Biopharma INC | $196.39 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $194.25 | 2019-2024 | |
| Sobi, INC | $190.99 | 2023-2025 | |
| Tersera Therapeutics LLC | $189.63 | 2022-2025 | Zoladex, Xermelo |
| Genzyme Corporation | $188.68 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $179.86 | 2022-2025 | Libtayo |
| Abbvie INC. | $151.85 | 2019-2025 | |
| Stemline Therapeutics INC. | $146.81 | 2023-2025 | Orserdu, Elzonris |
| Pharmacyclics LLC, An Abbvie Company | $141.76 | 2021-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $134.14 | 2019-2024 | Tazverik, Onivyde |
| Springworks Therapeutics, INC. | $133.16 | 2024-2025 | Ogsiveo, Gomekli |
| Alexion Pharmaceuticals, INC. | $117.19 | 2019-2024 | Ultomiris |
| Geron Corporation | $115.64 | 2024-2025 | Rytelo |
| Servier Pharmaceuticals LLC | $108.44 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $105.20 | 2023-2025 | Alymsys, Avastin, Neulasta |
| Pharmacosmos Therapeutics INC. | $104.61 | 2023-2025 | Cosela, Monoferric |
| Blueprint Medicines Corporation | $94.60 | 2021-2025 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $87.71 | 2021-2024 | Fotivda |
| Agios Pharmaceuticals, INC. | $85.83 | 2020-2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $84.14 | 2022-2025 | Clonoseq |
| Coherus Oncology, INC. | $83.33 | 2021-2022 | |
| Kite Pharma, INC. | $75.06 | 2022-2025 | Yescarta |
| Sun Pharmaceutical Industries INC. | $65.77 | 2022-2024 | Yonsa, Odomzo |
| Rigel Pharmaceuticals, INC. | $64.80 | 2019-2023 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $63.31 | 2023-2025 | Epkinly, Tivdak |
| Beone Medicines USA, INC. | $61.44 | 2025 | Tevimbra, Brukinsa |
| G1 Therapeutics, INC. | $59.43 | 2022-2023 | Cosela |
| Cti Biopharma Corp. | $56.77 | 2022-2023 | Vonjo |
| Adc Therapeutics America, INC. | $56.36 | 2022-2024 | |
| Mirati Therapeutics, INC. | $51.35 | 2023-2024 | Krazati |
| Tempus Ai, INC | $47.57 | 2024-2025 | Xt Cdx |
| Acceleron Pharma, INC. | $46.81 | 2020-2021 | |
| Accord Healthcare, INC. | $43.42 | 2025 | |
| Pharmaessentia USA Corporation | $42.33 | 2023-2025 | Besremi |
| Amag Pharmaceuticals, INC. | $38.88 | 2021-2022 | |
| Eusa Pharma (US) LLC | $38.34 | 2022 | |
| Recordati_rare_diseases_inc. | $37.78 | 2023-2024 | Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $35.37 | 2023 | |
| Spectrum Pharmaceuticals INC. | $34.27 | 2023-2025 | Rolvedon |
| Syndax Pharmaceuticals, INC. | $33.81 | 2025 | |
| Iovance Biotherapeutics, INC. | $31.38 | 2024-2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $31.01 | 2023-2024 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.41 | 2019-2023 | Gilotrif |
| Foundation Medicine, INC. | $26.47 | 2020-2023 | |
| Octapharma USA, INC. | $24.74 | 2025 | Octagam Immune Globulin (Human) |
| Dova Pharmaceuticals | $24.52 | 2020-2021 | |
| Deciphera Pharmaceuticals INC. | $23.09 | 2022 | |
| Progenics Pharmaceuticals, INC. | $22.36 | 2025 | |
| Blue Earth Diagnostics | $22.11 | 2023 | |
| Menarini Silicon Biosystems, INC. | $21.75 | 2023 | Cellsearch |
| Pharming Healthcare, INC. | $20.01 | 2023 | Ruconest |
| Innate Pharma, INC | $19.03 | 2020 | |
| Tesaro, INC. | $17.27 | 2019 | |
| Fennec Pharmaceuticals, INC. | $16.77 | 2024 | Pedmark |
| Tolmar Pharmaceuticals, INC. | $15.33 | 2019 | |
| Immunogen, INC. | $15.20 | 2023 | Elahere |
| Secura Bio, INC. | $14.81 | 2020 | |
| Heron Therapeutics, INC. | $12.94 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.91 | 2019 | |
| Clovis Oncology, INC. | $9.40 | 2019 |
Drugs and devices associated with these payments
Cabometyx $2,754Keytruda $569Lenvima $441Enhertu $392Jakafi $306Padcev $224Lynparza $222Kisqali $183Mektovi $172Braftovi $172Reblozyl $171Imbruvica $168Brukinsa $160Opdivo $151Monjuvi $147Zoladex $143Ibrance $143Lorbrena $142Libtayo $138Epkinly $132Jaypirca $131Orserdu $128Xpovio $123Pemazyre $122Inqovi $121Lonsurf $121Tukysa $119Vonjo $118Venclexta $117Rytelo $116Scemblix $113Verzenio $109Cosela $103Trodelvy $101Ojjaara $97.91Xalkori $97.26Retevmo $93.78Zepzelca $93.24Alunbrig $90.18Ogsiveo $80.07Erleada $78.96Pluvicto $78.08Ayvakit $76.68Tagrisso $70.14Xtandi $69.81Iclusig $63.64Imfinzi $63.11Yescarta $62.58Tibsovo $61.13Elrexfio $60.57Adcetris $60.54Tecentriq $58.17Akeega $57.62Bavencio $57.36Rybrevant $56.47Ultomiris $55.55Alymsys $54.59Fruzaqla $54.37Doptelet $54.32Clonoseq $54.18Fabhalta $53.79Pyrukynd $53.26Krazati $51.35Zejula $51.12Jemperli $51.12Avastin $50.61Polivy $50.56Lunsumio $50.56Pomalyst $49.87Tazverik $47.72Monoferric $46.49Vyloy $46.23Bosulif $46.15Alecensa $44.17Camcevi $43.42Yonsa $43.30Odomzo $43.30Besremi $42.33Inlyta $40.02Oxbryta $37.85Sylvant $37.78Promacta $37.58Phesgo $37.51Fotivda $37.33Tasigna $37.32Onivyde $36.96Synagis $36.93Welireg $36.06Comirnaty $35.03Darzalex $34.94Rozlytrek $34.40Rolvedon $34.27Sarclisa $33.50Tevimbra $33.11Amtagvi $31.38Vpriv $31.18Orgovyx $31.01Piqray $30.05Ziihera $30.00Tivdak $27.51
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.